Follow us on Twitter
twitter icon@FreshPatents


Dermatitis patents

      

This page is updated frequently with new Dermatitis-related patent applications.




Compositions and methods for treatment of inflammatory skin conditions using allantoin
Embodiments herein provide formulations and methods for treatment of inflammatory skin diseases using allantoin in an amount from about 0.5% to about 15.0% by weight. Inflammatory skin diseases treated by embodiments herein include, without limitation, cutaneous porphyria, sclerodema, epidermolysis bulosa, psoriasis, decubitus ulcers, pressure ulcers, diabetic ulcers, venous stasis ulcers, sickle cell ulcers, ulcers caused by burns, eczema, urticaria, atopic dermatitis, dermatitis herpetiform, contact dermatitis, arthritis, gout, lupus erythematosus, acne, alopecia, carcinomas, psoriasis, rosacea, miliaria, skin infections, post-operative care of incisions, post-operative skin care following any variety of plastic surgery operations, skin care following radiation treatment, care of dry, cracked or aged skin and skin lines as well as other conditions affecting the skin and having an inflammatory component, symptoms thereof, or a combination thereof.
Scioderm, Inc.


Compositions and methods of treatment of inflammatory skin conditions using allantoin
Embodiments herein provide formulations and methods for treatment of inflammatory skin diseases using allantoin in an amount from about 0.5% to about 15.0% by weight. Inflammatory skin diseases treated by embodiments herein include, without limitation, cutaneous porphyria, sclerodema, epidermolysis bulosa, psoriasis, decubitus ulcers, pressure ulcers, diabetic ulcers, venous stasis ulcers, sickle cell ulcers, ulcers caused by burns, eczema, urticaria, atopic dermatitis, dermatitis herpetiform, contact dermatitis, arthritis, gout, lupus erythematosus, acne, alopecia, carcinomas, psoriasis, rosacea, miliaria, skin infections, post-operative care of incisions, post-operative skin care following any variety of plastic surgery operations, skin care following radiation treatment, care of dry, cracked or aged skin and skin lines as well as other conditions affecting the skin and having an inflammatory component, symptoms thereof, or a combination thereof.
Scioderm, Inc.


Methods of treating diseases which are mediated by cutaneous lymphocyte antigen positive cells
The present invention relates to methods of treating patients suffering from itching and puritis mediated by cutaneous lymphocyte antigen positive t cell. In particular, diseases or disorders including contact dermatitis, drug induced delayed type cutaneous allergic reactions, toxic epidermal necrolysis, cutaneous t cell lymphoma, bullous pemphigoid, alopecia aereata, vitiligo, acne rosacea, prurigo nodularis, and herpes simplex virus, or combination thereof will benefit from the administration of an il-31 antagonist.
National Jewish Medical Research Center


Composition for improving skin conditions comprising a fragment of human heat shock protein 90a as an active ingredient
Liposomal and/or nano-liposomal encapsulated hsp90a, hpf polypeptide (115 aa) and novel polypeptides hpf Δc1 (101 aa) and hpfΔc2 (87 aa), as well as methods for manufacturing/preparing and using the compositions, are disclosed. Chimeric fusion proteins that include an hsp90a, hpf-polypeptide, hpf Δc1 or hpfΔc2 polypeptide are presented.
Regeron, Inc.


Temperature controlled hypoallergenic garments or pads
A hypoallergenic garment is provided that offers relief by achieving a desirable cooling or heating effect in an individual experiencing pain or discomfort. It can be used for treatment of conditions such as itching, burning, yeast or bacterial infection, urethral pain, inflammation, urinary tract infections, dermatitis, vaginal varicosity, menopausal perspiration, post-surgery swelling, edema due to a sports injury, swelling due to trauma, damage to the perineum, menopausal pain and combinations thereof..

Antibodies that specifically bind to tl1a
Recombinantly expressed variant antibodies that have enhanced affinity for tl1a and enhanced potency relative to the parent antibody from which they were derived are provided. The antibodies inhibit the interaction between tl1a and the death receptor 3 (dr3).
Cephalon, Inc.


Methods and systems for treatment of inflammatory diseases with nitric oxide
The present invention generally relates to compositions and methods for treatment of various inflammatory diseases, such as inflammatory dermatoses and other conditions, e.g., using nitric oxide. Examples of such dermatoses include psoriasis, atopic dermatitis, and contact dermatitis.
Transdermal Biotechnology, Inc.


Methods and compositions for dermatological use comprsing hydrocortisone acetate and biopolymers
Disclosed are compositions comprising hydrocortisone acetate and a biopolymer, chitosan, in a cream base, wherein the cream base comprises a primary and a secondary emulsifier, a waxy material, a co-solvent, a preservative, an acid, a chelating agent, a buffering agent, and water. The compositions disclosed herein are suitable for the treatment of dermatological conditions including but not limited to healing wounds and treatment of dermatitis..
Apex Laboratories Private Limited


New pyrazolyl-substituted heteroaryls and their use as medicaments
And the use of these aforementioned compounds for the treatment of diseases such as asthma, copd, allergic rhinitis, allergic dermatitis, lupus erythematodes, lupus nephritis and rheumatoid arthritis.. .

Composition comprising probiotic bacteria for use in the treatment of immune disorders
The present invention relates to a composition comprising probiotic bacteria for the treatment of pathologies associated with alterations of the immune system. In particular, the present invention relates to the use of selected probiotic bacteria for the preparation of a composition for the treatment of allergies, such as atopic dermatitis..
Probiotical S.p.a.


N-(pyrid-4-yl)amides and n-(pyrimidin-4-yl)amides and their pharmaceutical and cosmetic use

The present invention relates generally to the field of pharmaceuticals and cosmetics. More specifically, the present invention pertains to certain n-(pyrid-4-yl)amides and n-(pyrimidin-4-yl)amides of the following formula which are potent modulators (e.g., inhibitors) of an androgen receptor, and which are useful, for example, in therapy, for example, in the treatment of a dermatological disease or disorder; a disease or disorder of the sebaceous gland(s); acne; hyperseborrhoea; oily skin; seborrhoeic dermatitis; hyperpilosity or hirsutism; atopic dermatitis; or androgenic alopecia; especially acne.
Galderma Research & Development

Pharmaceutical use of 3, 4-bis-benzylsulfonylbutyronitrile

The present invention is directed to a method of treating inflammation or pain. The present invention is also directed to a method of treating an inflammatory skin disease or disorder, such as dermatitis, psoriasis, acne, or rosacea.
Olatec Therapeutics Llc

Medicament for treating peripheral neuropathies

The invention provides a method for treatment of the diseases in a human by identifying the human as one suffering from a herpes simplex virus (hsv), and then administering to the human the compound anti-hsv agent or a pharmaceutically acceptable salt thereof. The diseases include dermatosis and non-dermatosis, wherein the dermatosis include acnes, impetigo, pyoderma gangrenosum, chilblains and psoriasiform, asteatotic dermatitis, ichthyosis, lichen simplex chronicus (neurodermatitis, prurigo), seborrhoeic dermatitis, rosacea, perioral dermatitis, epidermal cyst, wound ulcer, discoid lupus erythematosus, vitiligo, alopecia, diagnostic criteria of some autoimmune diseases such as systemic lupus erythematosus or diabetic skin complications, wherein the non-dermatosis include glomerulonephritis, arthritis, crohn's disease, ulcerative colitis, myelodysplasia, multiple myeloma, demyelinating disease, parkinson's disease, anemia, cytopenia those among the diagnostic criteria..

Lactobacillus rhamnosus rht-3201 conjugated to polysaccharide polymer binder, and use thereof for prevention or treatment of atopic diseases

The present invention relates to heat-killed lactobacillus rhamnosus conjugated to a polysaccharide polymer binder, a preparation method therefor and a use thereof. The heat-killed lactobacillus rhamnosus conjugated to a polysaccharide polymer binder of the present invention has an excellent therapeutic effect for atopic diseases, and particularly has high industrial applicability because membrane adhesion competitiveness, which is an advantage of existing lactic acid bacteria, is significantly improved, thereby exhibiting dermatitis preventing, alleviating and treating effects of the same level as steroid-based drugs..
Il Dong Pharmaceutical Co., Ltd.

New compounds

The invention relates to a compound of formula (i) wherein the variables have the meaning as indicated in the claims; in free form and in salt form; and optionally the enantiomers and geometrical isomers thereof. The compounds of formula (i) are useful as therapeutic agent for organ transplants, lupus, multiple sclerosis, rheumatoid arthritis, psoriasis, type i diabetes and complications from diabetes, cancer, asthma, atopic dermatitis, autoimmune thyroid disorders, ulcerative colitis, inflammatory bowel diseases, crohn's disease, alzheimer's disease, leukemia, osteoarthritis, control of pruritus, chronic respiratory disease or keratoconjunctivitis in mammals..
Novartis Tiergesundheit Ag

Reducing cutaneous scar formation and treating skin conditions

The present invention provides methods of reducing cutaneous scar formation by treating a cutaneous wound with a composition comprising a therapeutic agent that is a sodium channel blocker and/or an inhibitor of the nax/scn7a pathway. The present invention also provides wound cover components impregnated with such compositions, kits composed of such compositions with a wound dressing or sterile wipe, and mixtures of such compositions with a topical component (e.g., cream, ointment, or gel) suitable for application to a cutaneous wound.
Northwestern University

Use of il-31 monoclonal antibodies for treating atopic dermatitis

The present invention relates to methods of treating pruritic diseases, including but not limited to contact dermatitis, atopic dermatitis, drug induced delayed type cutaneous allergic reactions, toxic epidermal necrolysis, cutaneous t cell lymphoma, bullous pemphigoid, alopecia wereata, vitiligo, acne rosacea, prurigo nodularis, scleroderma, herpes simplex virus, or combination thereof by administering il-31 monoclonal antibodies. The invention further provides the hybridomas that generate the monoclonal antibodies..
Zymogenetics, Inc.

Anti-human il-21 antibodies

Monoclonal antibodies are identified that bind the il-21 protein. These antibodies are used to identify regions of the il-21 protein to where binding neutralizes il-21 activity.
Zymogenetics, Inc.

Compositions for the treatment of peripheral ulcers of various origins

The present invention relates to combinations of an agent that stimulates cell proliferation and an anti-inflammatory/analgesic, which are useful in the treatment of peripheral ulcers of various origins, such as radiation dermatitis, diabetic ulcers, ulcers caused by venous stasis of the limbs, bedsores, and the associated skin infections, proctitis, vulvovaginitis and haemorrhoids with vascular lesions. These combinations can be presented as formulations for topical use..
Indena S.p.a.

Method for treating itching

The present invention relates to an anti-itching agent that prevents itch of skin and a method for treating itching. An emulsion, which is produced when sebum and sweat continuously secreted are mixed, contains a stimulatory composition having aqueous and oily properties and can be a causative agent of itch.
Lilac Laboratory Co., Ltd.

Anti-itching agent

The present invention relates to an anti-itching agent that prevents itch of skin. An emulsion, which is produced when sebum and sweat continuously secreted are mixed, contains a stimulatory composition having aqueous and oily properties and can be a causative agent of itch.
Lilac Laboratory Co., Ltd.

Skin barrier function improving agent

[effect] the followings are found: a jak inhibitor increases the expression amounts of filaggrin, loricrin, involucrin and β-defensin 3 as skin barrier function-related proteins; a jak inhibitor significantly increases nmf production in a tape stripping-treated mouse; and a jak inhibitor significantly accelerates a reduction in tewl in a dry skin mouse model, namely improves the skin barrier function. The jak inhibitor can be used as an active ingredient of a therapeutic or preventive agent for skin diseases such as senile xerosis, asteatosis, eczema, contact dermatitis, ichthyosis vulgaris, netherton syndrome, type b peeling skin syndrome, etc..

Prodrug of an ice inhibitor

Compound i is useful for treating il-1 mediated diseases such as rheumatoid arthritis, inflammatory bowel disease, crohn's disease, ulcerative colitis, inflammatory peritonitis, septic shock, pancreatitis, traumatic brain injury, organ transplant rejection, osteoarthritis, asthma, psoriasis, alzheimer's disease, myocardial infarction, congestive heart failure, huntington's disease, atherosclerosis, atopic dermatitis, leukemias and related disorders, myelodysplastic syndrome, uveitis or multiple myeloma.. .

Covalent granzyme b inhibitors

Covalent granzyme b inhibitors, compositions that include the compounds, and methods for using the compounds. A method for treating cutaneous scleroderma, epidermolysis bullosa, radiation dermatitis, alopecia areata, and discoid lupus erythematosus are provided..
Vida Therapeutics Inc.

Proline compounds as granzyme b inhibitors

Proline compounds as granzyme b inhibitors, compositions that include the compounds, and methods for using the compounds. Methods for treating cutaneous scleroderma, epidermolysis bullosa, radiation dermatitis, alopecia areata, and discoid lupus erythematosus are provided..
Vida Therapeutics Inc.

Pyrrole compounds as granzyme b inhibitors

Pyrrole compounds as granzyme b inhibitors, compositions that include the compounds, and methods for using the compounds. Method for treating cutaneous scleroderma, epidermolysis bullosa, radiation dermatitis, alopecia areata, and discoid lupus erythematosus are provided..
Vida Therapeutics Inc.

Heteroaryl syk inhibitors

The invention relates to new substituted heteroaryls of formula 1 wherein a is selected from the group consisting of n and ch d is selected from the group consisting of ch, n, nh, e is c, t is selected from the group consisting of c and n, g is selected from the group consisting of c and n, and wherein each of the broken (dotted) double bonds in ring 1 are selected from either a single bond or a double bond under the proviso that all single and double bonds of ring 1 are arranged in such a way that they all form together with ring 2 an aromatic ring system, and wherein r1, m and r3 are defined according to claim 1, and to the above compounds for the treatment of a disease selected from the group consisting of asthma, copd, allergic rhinitis, allergic dermatitis, lupus erythematodes, lupus nephritis and rheumatoid arthritis.. .
Boehringer Ingelheim International Gmbh

Compound of the avermectin family or of the milbemycin family for the treatment and/or prevention of atopic dermatitis

A pharmaceutical composition is described that includes a compound of the avermectin family, possibly ivermectin, or a compound of the milbemycin family in a pharmaceutically acceptable carrier, for use in the treatment and/or prevention of atopic dermatitis.. .
Galderma S.a.

Composition for treating or preventing inflammatory skin disease, comprising, as active ingredient, immature citrus fruit extract, or synephrine or salt thereof

The present invention relates to a composition for treating or preventing an inflammatory skin disease, comprising, as an active ingredient, an unripe citrus unshiu fruit extract and/or synephrine or salt thereof. The composition of the present invention prevents an inflammatory reaction by inhibiting activity of stat6, expression of eotaxin-1 and an agglomeration function of eosinophil, and thus, shows effects of preventing and treating an allergic inflammatory disease, atopic dermatitis, eczema, psoriasis, etc.
Boi Sperctrum, Inc.

Agent for the treatment of skin conditions

Disclosed are methods of treatment and compositions containing at least one non-volatile silicone oil in combination with at least one spreading agent for use in the treatment of skin conditions in mammals typified by scales, plaques and scabs and associated with punctiform bleeding during the removal of scales, plaque or scabs. Preferred conditions are selected from the group consisting of seborrheic dermatitis, psoriasis, and cradle cap wherein the incidence of punctiform bleeding and formation of bloody tear points on the skin during removal of the scales is diminished or prevented..
G. Pohl-boskamp Gmbh & Co. Kg



Dermatitis topics:
  • Dermatitis
  • Antibodies
  • Bispecific Antibodies
  • Atopic Dermatitis
  • Aspergillosis
  • Inflammation
  • Tinea Cruris
  • Tinea Pedis
  • Tinea Manuum
  • Diaper Rash
  • Prophylactic
  • Allergic Rhinitis
  • Angioedema
  • Contact Dermatitis
  • Mastocytosis


  • Follow us on Twitter
    twitter icon@FreshPatents

    ###

    This listing is a sample listing of patent applications related to Dermatitis for is only meant as a recent sample of applications filed, not a comprehensive history. There may be associated servicemarks and trademarks related to these patents. Please check with patent attorney if you need further assistance or plan to use for business purposes. This patent data is also published to the public by the USPTO and available for free on their website. Note that there may be alternative spellings for Dermatitis with additional patents listed. Browse our RSS directory or Search for other possible listings.


    0.2622

    file did exist - 2669

    1 - 1 - 54